vs
Amphastar Pharmaceuticals, Inc.（AMPH）与PATHWARD FINANCIAL, INC.（CASH）财务数据对比。点击上方公司名可切换其他公司
Amphastar Pharmaceuticals, Inc.的季度营收约是PATHWARD FINANCIAL, INC.的1.1倍（$183.1M vs $173.1M），PATHWARD FINANCIAL, INC.净利率更高（20.3% vs 13.3%，领先7.0%），PATHWARD FINANCIAL, INC.同比增速更快（-0.2% vs -1.8%），PATHWARD FINANCIAL, INC.自由现金流更多（$104.1M vs $24.6M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs -18.0%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
AMPH vs CASH — 直观对比
营收规模更大
AMPH
是对方的1.1倍
$173.1M
营收增速更快
CASH
高出1.6%
-1.8%
净利率更高
CASH
高出7.0%
13.3%
自由现金流更多
CASH
多$79.5M
$24.6M
两年增速更快
AMPH
近两年复合增速
-18.0%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $173.1M |
| 净利润 | $24.4M | $35.2M |
| 毛利率 | 46.8% | — |
| 营业利润率 | 19.4% | 24.6% |
| 净利率 | 13.3% | 20.3% |
| 营收同比 | -1.8% | -0.2% |
| 净利润同比 | -35.7% | 11.9% |
| 每股收益（稀释后） | $0.51 | $1.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHCASH
| Q4 25 | $183.1M | $173.1M | ||
| Q3 25 | $191.8M | $186.7M | ||
| Q2 25 | $174.4M | $195.8M | ||
| Q1 25 | $170.5M | $274.8M | ||
| Q4 24 | $186.5M | $182.6M | ||
| Q3 24 | $191.2M | $179.5M | ||
| Q2 24 | $182.4M | $188.6M | ||
| Q1 24 | $171.8M | $257.6M |
净利润AMPHCASH
| Q4 25 | $24.4M | $35.2M | ||
| Q3 25 | $17.4M | $38.8M | ||
| Q2 25 | $31.0M | $42.1M | ||
| Q1 25 | $25.3M | $75.0M | ||
| Q4 24 | $38.0M | $30.0M | ||
| Q3 24 | $40.4M | $33.5M | ||
| Q2 24 | $37.9M | $44.9M | ||
| Q1 24 | $43.2M | $69.9M |
毛利率AMPHCASH
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
营业利润率AMPHCASH
| Q4 25 | 19.4% | 24.6% | ||
| Q3 25 | 13.2% | 25.9% | ||
| Q2 25 | 24.2% | 24.1% | ||
| Q1 25 | 21.9% | 33.2% | ||
| Q4 24 | 24.2% | 19.8% | ||
| Q3 24 | 29.8% | 20.9% | ||
| Q2 24 | 30.3% | 27.1% | ||
| Q1 24 | 27.9% | 33.8% |
净利率AMPHCASH
| Q4 25 | 13.3% | 20.3% | ||
| Q3 25 | 9.0% | 20.8% | ||
| Q2 25 | 17.8% | 21.5% | ||
| Q1 25 | 14.8% | 27.3% | ||
| Q4 24 | 20.4% | 16.4% | ||
| Q3 24 | 21.1% | 18.7% | ||
| Q2 24 | 20.8% | 23.8% | ||
| Q1 24 | 25.1% | 27.1% |
每股收益（稀释后）AMPHCASH
| Q4 25 | $0.51 | $1.57 | ||
| Q3 25 | $0.37 | $1.69 | ||
| Q2 25 | $0.64 | $1.81 | ||
| Q1 25 | $0.51 | $3.14 | ||
| Q4 24 | $0.74 | $1.23 | ||
| Q3 24 | $0.78 | $1.34 | ||
| Q2 24 | $0.73 | $1.78 | ||
| Q1 24 | $0.81 | $2.74 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $331.2M |
| 总债务越低越好 | $608.7M | $33.5M |
| 股东权益账面价值 | $788.8M | $854.5M |
| 总资产 | $1.6B | $7.6B |
| 负债/权益比越低杠杆越低 | 0.77× | 0.04× |
8季度趋势，按日历期对齐
现金及短期投资AMPHCASH
| Q4 25 | $282.8M | $331.2M | ||
| Q3 25 | $276.2M | $120.6M | ||
| Q2 25 | $231.8M | $258.3M | ||
| Q1 25 | $236.9M | $254.2M | ||
| Q4 24 | $221.6M | $597.4M | ||
| Q3 24 | $250.5M | $158.3M | ||
| Q2 24 | $217.8M | $298.9M | ||
| Q1 24 | $289.6M | $347.9M |
总债务AMPHCASH
| Q4 25 | $608.7M | $33.5M | ||
| Q3 25 | $608.6M | $33.5M | ||
| Q2 25 | $607.7M | $33.4M | ||
| Q1 25 | $603.9M | $33.4M | ||
| Q4 24 | $601.6M | $33.4M | ||
| Q3 24 | $596.4M | $33.4M | ||
| Q2 24 | $586.9M | $33.3M | ||
| Q1 24 | $594.0M | $33.4M |
股东权益AMPHCASH
| Q4 25 | $788.8M | $854.5M | ||
| Q3 25 | $776.7M | $858.0M | ||
| Q2 25 | $757.5M | $819.0M | ||
| Q1 25 | $751.3M | $814.7M | ||
| Q4 24 | $732.3M | $758.3M | ||
| Q3 24 | $727.7M | $822.5M | ||
| Q2 24 | $713.3M | $748.4M | ||
| Q1 24 | $672.4M | $719.5M |
总资产AMPHCASH
| Q4 25 | $1.6B | $7.6B | ||
| Q3 25 | $1.7B | $7.2B | ||
| Q2 25 | $1.6B | $7.2B | ||
| Q1 25 | $1.6B | $7.0B | ||
| Q4 24 | $1.6B | $7.6B | ||
| Q3 24 | $1.5B | $7.5B | ||
| Q2 24 | $1.5B | $7.5B | ||
| Q1 24 | $1.6B | $7.4B |
负债/权益比AMPHCASH
| Q4 25 | 0.77× | 0.04× | ||
| Q3 25 | 0.78× | 0.04× | ||
| Q2 25 | 0.80× | 0.04× | ||
| Q1 25 | 0.80× | 0.04× | ||
| Q4 24 | 0.82× | 0.04× | ||
| Q3 24 | 0.82× | 0.04× | ||
| Q2 24 | 0.82× | 0.04× | ||
| Q1 24 | 0.88× | 0.05× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $108.3M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $104.1M |
| 自由现金流率自由现金流/营收 | 13.4% | 60.1% |
| 资本支出强度资本支出/营收 | 4.5% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.35× | 3.08× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $616.8M |
8季度趋势，按日历期对齐
经营现金流AMPHCASH
| Q4 25 | $32.9M | $108.3M | ||
| Q3 25 | $52.6M | $303.7M | ||
| Q2 25 | $35.6M | $30.4M | ||
| Q1 25 | $35.1M | $188.3M | ||
| Q4 24 | $29.0M | $-71.7M | ||
| Q3 24 | $60.0M | $143.1M | ||
| Q2 24 | $69.1M | $113.2M | ||
| Q1 24 | $55.3M | $203.0M |
自由现金流AMPHCASH
| Q4 25 | $24.6M | $104.1M | ||
| Q3 25 | $47.2M | $300.3M | ||
| Q2 25 | $25.0M | $27.7M | ||
| Q1 25 | $24.4M | $184.7M | ||
| Q4 24 | $16.6M | $-73.8M | ||
| Q3 24 | $46.2M | $138.8M | ||
| Q2 24 | $63.1M | $111.0M | ||
| Q1 24 | $46.5M | $201.3M |
自由现金流率AMPHCASH
| Q4 25 | 13.4% | 60.1% | ||
| Q3 25 | 24.6% | 160.9% | ||
| Q2 25 | 14.3% | 14.1% | ||
| Q1 25 | 14.3% | 67.2% | ||
| Q4 24 | 8.9% | -40.4% | ||
| Q3 24 | 24.1% | 77.3% | ||
| Q2 24 | 34.6% | 58.8% | ||
| Q1 24 | 27.1% | 78.1% |
资本支出强度AMPHCASH
| Q4 25 | 4.5% | 2.4% | ||
| Q3 25 | 2.8% | 1.8% | ||
| Q2 25 | 6.1% | 1.4% | ||
| Q1 25 | 6.3% | 1.3% | ||
| Q4 24 | 6.7% | 1.1% | ||
| Q3 24 | 7.2% | 2.4% | ||
| Q2 24 | 3.3% | 1.2% | ||
| Q1 24 | 5.1% | 0.7% |
现金转化率AMPHCASH
| Q4 25 | 1.35× | 3.08× | ||
| Q3 25 | 3.03× | 7.83× | ||
| Q2 25 | 1.15× | 0.72× | ||
| Q1 25 | 1.39× | 2.51× | ||
| Q4 24 | 0.76× | -2.39× | ||
| Q3 24 | 1.48× | 4.27× | ||
| Q2 24 | 1.82× | 2.52× | ||
| Q1 24 | 1.28× | 2.90× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CASH
| Consumer | $103.0M | 59% |
| Payment Card And Deposit Fees | $30.1M | 17% |
| Other | $24.2M | 14% |
| Rental Income | $11.6M | 7% |
| Commercial | $4.2M | 2% |
